晚期卵巢癌可干预基因致病性变异患病率:全国登记研究NGS分析
基于韩国全国NGS登记数据,纳入779例晚期卵巢癌患者,分析55个理论可干预基因。81.5%患者携带致病性变异,TP53(61.5%)、BRCA1(12.2%)、PIK3CA(10.4%)、KRAS(10.3%)、BRCA2(9.6%)和PTEN(3.7%)为常见突变。49.2%患者至少有一个理论可干预基因致病突变,TP53野生型肿瘤中BRCA1/2致病突变占14.0%。
要点
- 晚期卵巢癌中81.5%携带致病性变异,49.2%有理论可干预基因突变。
- TP53野生型肿瘤中BRCA1/2致病突变率为14.0%(95%CI 10-18%)。
- 无BRCA1/2突变者常见KRAS(12.2%)、PIK3CA(10.4%)和PTEN(4.2%)突变。
核心结论
- 近半数晚期卵巢癌患者可视为基因组医学的理论候选者。
- 无TP53突变患者中仍存在相当比例的BRCA1/2致病突变。
研究设计与样本
- 研究为基于韩国全国NGS登记数据的回顾性分析,纳入2017年3月至2018年12月接受NGS检测的779例晚期卵巢癌患者。
- 分析了55个理论可干预基因,将58个突变报告为致病性变异(含可能致病性变异)。
主要发现
- 致病性突变总体患病率为81.5%,11.6%患者既无致病突变也无意义不明变异。
- 至少3%患者共有的常见致病突变为TP53(61.5%)、BRCA1(12.2%)、PIK3CA(10.4%)、KRAS(10.3%)、BRCA2(9.6%)和PTEN(3.7%)。
- TP53野生型肿瘤中BRCA1/2致病突变占14.0%(42/300,95%CI 10-18%),约占全部BRCA1/2致病突变的25.9%。
- 49.2%患者至少有一个理论可干预基因的致病突变;无BRCA1/2突变者中KRAS突变12.2%、PIK3CA突变10.4%、PTEN突变4.2%。
- PTCH1突变与ATM、NF1、ERBB2和MTOR突变相关(校正P值分别为0.0054、0.0035、0.0010和0.0003)。
临床怎么用
- 对晚期卵巢癌患者进行NGS检测可识别近半数理论可干预基因突变,支持基因组医学候选筛选。
- TP53野生型患者仍应关注BRCA1/2致病突变,无BRCA1/2突变者需注意KRAS、PIK3CA和PTEN等可干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We examined the actionable genomic alterations in ovarian cancer by analysing the nationwide registry of next-generation sequencing (NGS) data. METHODS: From March 2017 to December 2018, 16,458 patients with cancer underwent NGS testing under the interim coverage programme for NGS provided by the National Health Insurance of Korea. Among these patients, 779 patients had advanced ovarian cancer. Fifty-eight mutations were reported as pathogenic variants, which included likely pathogenic variants, and 55 theoretically actionable genes were analysed. RESULTS: The prevalence of pathogenic mutations in the population was 81.5%, whereas 11.6% of the population had neither a pathogenic mutation nor a variant of unknown significance. Common pathogenic mutations shared by at least 3% of the study population were mutations in TP53 (61.5%), BRCA1 (12.2%), PIK3CA (10.4%), KRAS (10.3%), BRCA2 (9.6%) and PTEN (3.7%). BRCA1/2 pathogenic mutations were found in 14.0% (42 of 300, 95% confidence interval = 10-18%) of the patients with TP53 wild-type tumours, comprising approximately one-quarter (25.9%) of the total observed BRCA1/2 pathogen mutations. At least one pathogenic mutation in a theoretically actionable gene was found in 49.2% of patients. Among patients without a BRCA1/2 pathogenic mutation, mutations were frequently observed in KRAS (12.2%), PIK3CA (10.4%) and PTEN (4.2%). PTCH1 mutations were correlated with ATM, NF1, ERBB2 and MTOR mutations (adjusted p = 0.0054, p = 0.0035, p = 0.0010 and p = 0.0003, respectively). CONCLUSIONS: Almost half of patients with ovarian cancer could be estimated as theoretical candidates for genomic medicine. Substantial BRCA1/2 pathogenic mutations were observed in patients not harbouring a TP53 mutation.
引用
- Kang S, Yu YL, Cho SY, et al. Prevalence of pathogenic variants in actionable genes in advanced ovarian cancer: a next-generation sequencing analysis of a nationwide registry study. Eur J Cancer. 2020. PMID: 33166861. doi:10.1016/j.ejca.2020.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。